P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer

Modern Pathology

Volumn 24, Issue 1, 2011, Pages 64-81

  Turashvili, Gulisa ^a   McKinney, Steven E ^a   Goktepe, Ozge ^a   Leung, Samuel C ^b   Huntsman, David G ^b   Gelmon, Karen A ^c   Los, Gerrit ^d   Rejto, Paul A ^d   Aparicio, Samuel A J R ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d PFIZER INC   (United States)

Author keywords

breast cancer; immunohistochemistry; P cadherin; prognosis; tissue microarray

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY KI 67; P CADHERIN; PROTEIN BCL 2; PROTEIN P53; Y BOX BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FISHER EXACT TEST; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY;

ADULT; AGED; BREAST NEOPLASMS; CADHERINS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650921170     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.189     Document Type: Article

References (86)

1. Furukawa F, Fujii K, Horiguchi Y, et al. Roles of E- and P-cadherin in the human skin. Microsc Res Tech 1997;38:343-352.
2. Furukawa F, Takigawa M, Matsuyoshi N, et al. Cadherins in cutaneous biology. J Dermatol 1994;21:802-813.
3. Nose A, Nagafuchi A, Takeichi M. Isolation of placental cadherin cDNA: identification of a novel gene family of cell-cell adhesion molecules. EMBO J 1987;6:3655-3661.
4. Derycke L, De Wever O, Stove V, et al. Soluble N-cadherin in human biological fluids. Int J Cancer 2006;119:2895-2900.
5. Paredes J, Correia AL, Ribeiro AS, et al. P-cadherin expression in breast cancer: a review. Breast Cancer Res 2007;9:214.
6. Hines MD, Jin HC, Wheelock MJ, et al. Inhibition of cadherin function differentially affects markers of terminal differentiation in cultured human keratino-cytes. J Cell Sci 1999;112:4569-4579.
7. Radice GL, Ferreira-Cornwell MC, Robinson SD, et al. Precocious mammary gland development in P-cadher-in-deficient mice. J Cell Biol 1997;139:1025-1032.
8. Knudsen KA, Wheelock MJ. Cadherins and the mammary gland. J Cell Biochem 2005;95:488-496.
9. Kovacs A, Walker RA. P-cadherin as a marker in the differential diagnosis of breast lesions. J Clin Pathol 2003;56:139-141.
10. Soler AP, Russo J, Russo IH, et al. Soluble fragment of P-cadherin adhesion protein found in human milk. J Cell Biochem 2002;85:180-184.
11. De Paul AL, Bonaterra M, Soler AP, et al. Soluble p-cadherin found in human semen. J Androl 2005; 26:44-47.
12. Mannello F, Tonti GA, Medda V, et al. Increased shedding of soluble fragments of P-cadherin in nipple aspirate fluids from women with breast cancer. Cancer Sci 2008;99:2160-2169.
13. Knudsen KA, Lin CY, Johnson KR, et al. Lack of correlation between serum levels of E- and P-cadherin fragments and the presence of breast cancer. Hum Pathol 2000;31:961-965.
14. Paredes J, Milanezi F, Viegas L, et al. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch 2002;440:16-21.
15. Palacios J, Benito N, Pizarro A, et al. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. Am J Pathol 1995;146:605-612.
16. Rasbridge SA, Gillett CE, Sampson SA, et al. Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol 1993;169: 245-250.
17. Peralta Soler A, Knudsen KA, Salazar H, et al. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999;86:1263-1272.
18. Madhavan M, Srinivas P, Abraham E, et al. Cadherins as predictive markers of nodal metastasis in breast cancer. Mod Pathol 2001;14:423-427.
19. Paredes J, Albergaria A, Oliveira JT, et al. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res 2005;11:5869-5877.
20. Gamallo C, Moreno-Bueno G, Sarrio D, et al. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. Mod Pathol 2001;14:650-654.
21. Kovacs A, Dhillon J, Walker RA. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. Mol Pathol 2003; 56:318-322.
22. Paredes J, Milanezi F, Reis-Filho JS, et al. Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer? Pathol Res Pract 2002;198:795-801.
23. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-752.
24. Matos I, Dufloth R, Alvarenga M, et al. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688-694.
25. Paredes J, Lopes N, Milanezi F, et al. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 2007;450:73-80.
26. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
27. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol 2009;20:1913-1927.
28. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-1376.
29. Cheang MC, Treaba DO, Speers CH, et al. Immuno-histochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 2006;24:5637-5644.
30. Chia S, Norris B, Speers C, et al. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol 2008;26:5697-5704.
31. Habibi G, Leung S, Law JH, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 2008;10:R86.
32. Jensen KC, Turbin DA, Leung S, et al. New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat 2008;112:453-459.
33. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-750.
34. Turashvili G, Leung S, Turbin D, et al. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer 2009;9:165.
35. Liu S, Chia SK, Mehl E, et al. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 2010;119:53-61.
36. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin Radiat Oncol 2008;18:89-97.
37. Stefansson IM, Salvesen HB, Akslen LA. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 2004;22:1242-1252.
38. Nalwoga H, Arnes JB, Wabinga H, et al. Frequency of the basal-like phenotype in African breast cancer. APMIS 2007;115:1391-1399.
39. Arnes JB, Brunet JS, Stefansson I, et al. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 2005;11: 4003-4011.
40. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immu-nohistochemistry staining data obtained with tissue microarrays. Am J Pathol 2002;161:1557-1565.
41. Liu CL, Montgomery KD, Natkunam Y, et al. TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol 2005;18:1641-1648.
42. The R Project for Statistical Computing Available from at http://www.r-project.org.
43. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model, Vol. XIII, Springer: New York, 2001, p 350.
44. Rajput AB, Turbin DA, Cheang MC, et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. Breast Cancer Res Treat 2008;107:249-257.
45. Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference, and Prediction. Springer: New York, 2001, p 533.
46. Rifai N, Altman DG, Bossuyt PM. Reporting bias in diagnostic and prognostic studies: time for action. Clin Chem 2008;54:1101-1103.
47. Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005;14: 1108-1112.
48. Ben Hamida A, Labidi IS, Mrad K, et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 2008;8:28.
49. Troxell ML, Masek M, Sibley RK. Immunohistochem-ical staining of papillary breast lesions. Appl Immu-nohistochem Mol Morphol 2007;15:145-153.
50. Crabb SJ, Bajdik CD, Leung S, et al. Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. Breast Cancer Res 2008;10:R6.
51. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-1485.
52. van Belle G, Fisher LD, Heagerty PJ, et al. Biostatistics: A Methodology for the Health Sciences. John Wiley and Sons: New Jersey, 2004, p 896.
53. Nout RA, Fiets WE, Struikmans H, et al. The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 2008;109:567-572.
54. Gusterson B. Do 'basal-like' breast cancers really exist? Nat Rev Cancer 2009;9:128-134.
55. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657.
56. Nielsen TO, Hsu FD, Jensen K, et al. Immunohisto-chemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367-5374.
57. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
58. Han AC, Soler AP, Knudsen KA, et al. Distinct cadherin profiles in special variant carcinomas and other tumors of the breast. Hum Pathol 1999;30:1035-1039.
59. Reis-Filho JS, Milanezi F, Paredes J, et al. Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. Appl Immunohistochem Mol Morphol 2003;11:1-8.
60. Jacquemier J, Padovani L, Rabayrol L, et al. Typical medullary breast carcinomas have a basal/myoepithe-lial phenotype. J Pathol 2005;207:260-268.
61. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
62. Fulford LG, Easton DF, Reis-Filho JS, et al. Specific morphological features predictive for the basal pheno-type in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.
63. Reis-Filho JS, Milanezi F, Steele D, et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
64. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008;52:108-118.
65. McCarthy A, Savage K, Gabriel A, et al. A mouse model of basal-like breast carcinoma with metaplastic elements. J Pathol 2007;211:389-398.
66. Rakha EA, El-Sheikh SE, Kandil MA, et al. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008;39:857-865.
67. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-5180.
68. Honrado E, Benitez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005;18: 1305-1320.
69. Palacios J, Honrado E, Osorio A, et al. Immunohisto-chemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-3614.
70. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immuno-histochemical markers. Breast Cancer Res Treat 2005; 90:5-14.
71. Arnes JB, Begin LR, Stefansson I, et al. Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol 2009;62:139-146.
72. Arnes JB, Collett K, Akslen LA. Independent prognostic value of the basal-like phenotype of breast cancer and associations with EGFR and candidate stem cell marker BMI-1. Histopathology 2008;52:370-380.
73. Ribeiro AS, Albergaria A, Sousa B, et al. Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene 2010;29:392-402.
74. Sarrio D, Palacios J, Hergueta-Redondo M, et al. Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer 2009;9:74.
75. Cleton-Jansen AM. E-cadherin and loss of heterozyg-osity at chromosome 16 in breast carcinogenesis: different genetic pathways in ductal and lobular breast cancer? Breast Cancer Res 2002;4:5-8.
76. Berx G, Becker KF, Hofler H, et al. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 1998;12: 226-237.
77. Cowin P, Rowlands TM, Hatsell SJ. Cadherins and catenins in breast cancer. Curr Opin Cell Biol 2005; 17:499-508.
78. Yoder BJ, Wilkinson EJ, Massoll NA. Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast. Breast J 2007;13:172-179.
79. Guarino M, Rubino B, Ballabio G. The role of epithelial-mesenchymal transition in cancer pathology. Pathology 2007;39:305-318.
80. Boyer B, Valles AM, Edme N. Induction and regulation of epithelial-mesenchymal transitions. Biochem Pharmacol 2000;60:1091-1099.
81. Paredes J, Correia AL, Ribeiro AS, et al. Breast carcinomas that co-express E- and P-cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival. J Clin Pathol 2008;61: 856-862.
82. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoe-diting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-998.
83. Storkus WJ, Falo Jr LD. A 'good death' for tumor immunology. Nat Med 2007;13:28-30.
84. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2: 277-288.
85. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007;13:54-61. (Pubitemid 46067386)
86. Imai K, Hirata S, Irie A, et al. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 2008; 14:6487-6495.